Dear Colleague,

Rarely have we faced so many daunting clinical challenges in infectious disease with so few clinical choices in our armamentarium. Equally rarely have we had so few potential agents in development to treat these emerging and expanding pathogens. The increased incidence of multi-resistant Gram positive species such as MRSA in the community and pan-resistant Gram negative organisms in the hospital setting are posing major health care challenges. Efforts to control these and other epidemic species such as Clostridium difficile cannot be achieved with antibiotic stewardship alone, and new agents are needed now.

GTCbio’s 2010 7th Annual Anti-infectives Partnering and Deal-Making Summit taking places on October 7-8, 2010 in Boston will contribute to the on-going battle against the ever-changing infectious threats by having experts with direct experiences in the field discuss a wide variety of topics on infectious diseases. These topics will include reviews of both established and emerging classes of anti-infectives (including antibacterials , antifungals and anti-virals), a US perspective on the regulatory challenges in addition to subjects including portfolio value management, license revenue and patent extension strategies and much more. The agenda also allows time for networking and opportunities to interface with speakers and fellow delegates in a collegial setting. Previous GTCBio conferences have been catalytic to several successful partnerships and in 2010 we expect this trend to continue.

GTCbio’s Anti-Infectives Partnering & Deal Making-Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry. This event also provides a unique venue for attendees to learn about the anti-infective business development trends, the infectious disease markets, and novel technologies that shape up the industry.

The Sessions of the conference include:

I – Recent Advances in Anti-Infectives Development – Part I – Anti-viral
II – Recent Advances in Anti-Infectives Development – Part II – Anti-bacterial
III – Scientific & Regulatory Updates
IV – Innovative Alliance & Licensing Strategies
V – Current Models of R&D Collaboration – Part 1 – Anti-Bacterial
VI – Current Models of R&D Collaboration – Part 2 – Anti-Viral and Anti-Fungal
VI – Investment Opportunities in the Anti-Infectives Space

Register by September 7 for a 10% Discount. Or, Register 2, the 3rd goes free!

Best regards,

2010 Anti-Infectives Summit Advisory Committee